Gt Biopharma Stock Price History
GTBP Stock | USD 2.40 0.16 6.25% |
Below is the normalized historical share price chart for GT Biopharma extending back to November 05, 1984. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of GT Biopharma stands at 2.40, as last reported on the 18th of March 2025, with the highest price reaching 2.55 and the lowest price hitting 2.40 during the day.
If you're considering investing in GTBP Stock, it is important to understand the factors that can impact its price. GT Biopharma appears to be very risky, given 3 months investment horizon. GT Biopharma retains Efficiency (Sharpe Ratio) of 0.0665, which attests that the entity had a 0.0665 % return per unit of price deviation over the last 3 months. By inspecting GT Biopharma's technical indicators, you can evaluate if the expected return of 0.65% is justified by implied risk. Please utilize GT Biopharma's Standard Deviation of 9.75, market risk adjusted performance of 0.2721, and Semi Deviation of 6.11 to validate if our risk estimates are consistent with your expectations.
At this time, GT Biopharma's Other Stockholder Equity is relatively stable compared to the past year. As of 03/18/2025, Stock Based Compensation To Revenue is likely to grow to 131.64, though Total Stockholder Equity is likely to grow to (1.6 M). . As of 03/18/2025, Price To Sales Ratio is likely to drop to 2,293. In addition to that, Price Earnings Ratio is likely to grow to -0.42. GTBP Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 22nd of September 2017 | 200 Day MA 3.1278 | 50 Day MA 2.6253 | Beta 0.57 |
GTBP |
Sharpe Ratio = 0.0665
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | GTBP | |||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
Negative Returns |
Estimated Market Risk
9.78 actual daily | 87 87% of assets are less volatile |
Expected Return
0.65 actual daily | 12 88% of assets have higher returns |
Risk-Adjusted Return
0.07 actual daily | 5 95% of assets perform better |
Based on monthly moving average GT Biopharma is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of GT Biopharma by adding it to a well-diversified portfolio.
GT Biopharma Stock Price History Chart
There are several ways to analyze GTBP Stock price data. The simplest method is using a basic GTBP candlestick price chart, which shows GT Biopharma price history and the buying and selling dynamics of a specified period. Many traders also use subjective judgment to their trading calls, avoiding the need to trade based on technical analysis.
Highest Price | December 24, 2024 | 3.2 |
Lowest Price | December 20, 2024 | 1.75 |
GT Biopharma March 18, 2025 Stock Price Synopsis
Various analyses of GT Biopharma's daily price changes, such as its Balance Of Power or Price Action, are crucial when deciding whether to buy, hold, or sell GTBP Stock. It can be used to describe the percentage change in the price of GT Biopharma from one trading day to the next and could be a valuable metric for traders and investors to gauge the volatility and momentum of GTBP Stock.GT Biopharma Price Rate Of Daily Change | 0.94 | |
GT Biopharma Price Daily Balance Of Power | (1.07) | |
GT Biopharma Accumulation Distribution | 5,397 | |
GT Biopharma Price Action Indicator | (0.16) |
GT Biopharma March 18, 2025 Stock Price Analysis
GTBP Stock Price History Data
The price series of GT Biopharma for the period between Wed, Dec 18, 2024 and Tue, Mar 18, 2025 has a statistical range of 1.45 with a coefficient of variation of 13.46. Under current investment horizon, the daily prices are spread out with arithmetic mean of 2.43. The median price for the last 90 days is 2.38. The company completed 1:30 stock split on 5th of February 2024. GT Biopharma completed dividends distribution on 2017-08-21.Open | High | Low | Close | Volume | ||
03/17/2025 | 2.55 | 2.55 | 2.40 | 2.40 | 91,750 | |
03/14/2025 | 2.48 | 2.56 | 2.32 | 2.56 | 20,465 | |
03/13/2025 | 2.44 | 2.65 | 2.42 | 2.48 | 61,019 | |
03/12/2025 | 2.47 | 2.53 | 2.34 | 2.49 | 47,231 | |
03/11/2025 | 2.47 | 2.54 | 2.32 | 2.48 | 41,254 | |
03/10/2025 | 2.44 | 2.57 | 2.38 | 2.49 | 31,480 | |
03/07/2025 | 2.32 | 2.56 | 2.30 | 2.44 | 53,546 | |
03/06/2025 | 2.33 | 2.53 | 2.28 | 2.37 | 59,611 | |
03/05/2025 | 2.25 | 2.43 | 2.21 | 2.43 | 80,177 | |
03/04/2025 | 2.34 | 2.42 | 2.11 | 2.18 | 44,404 | |
03/03/2025 | 2.40 | 2.43 | 2.23 | 2.33 | 55,375 | |
02/28/2025 | 2.30 | 2.47 | 2.14 | 2.38 | 59,043 | |
02/27/2025 | 2.15 | 2.40 | 2.09 | 2.30 | 92,425 | |
02/26/2025 | 2.04 | 2.38 | 2.03 | 2.36 | 355,174 | |
02/25/2025 | 2.46 | 3.12 | 2.02 | 2.46 | 26,668,992 | |
02/24/2025 | 2.19 | 2.19 | 2.03 | 2.03 | 14,612 | |
02/21/2025 | 2.13 | 2.23 | 2.08 | 2.15 | 17,151 | |
02/20/2025 | 2.11 | 2.25 | 2.07 | 2.13 | 7,797 | |
02/19/2025 | 2.08 | 2.25 | 2.08 | 2.11 | 15,452 | |
02/18/2025 | 2.08 | 2.27 | 2.08 | 2.10 | 15,611 | |
02/14/2025 | 2.29 | 2.29 | 2.08 | 2.14 | 21,840 | |
02/13/2025 | 2.13 | 2.24 | 2.13 | 2.24 | 27,482 | |
02/12/2025 | 2.15 | 2.26 | 2.12 | 2.13 | 7,598 | |
02/11/2025 | 2.20 | 2.38 | 2.10 | 2.11 | 40,647 | |
02/10/2025 | 2.15 | 2.21 | 2.03 | 2.21 | 9,624 | |
02/07/2025 | 2.24 | 2.38 | 2.15 | 2.15 | 17,164 | |
02/06/2025 | 2.16 | 2.36 | 2.16 | 2.19 | 18,773 | |
02/05/2025 | 2.39 | 2.39 | 2.20 | 2.27 | 25,976 | |
02/04/2025 | 2.10 | 2.31 | 2.10 | 2.20 | 25,487 | |
02/03/2025 | 2.16 | 2.27 | 2.11 | 2.25 | 36,459 | |
01/31/2025 | 2.06 | 2.23 | 2.01 | 2.23 | 20,880 | |
01/30/2025 | 2.08 | 2.19 | 2.02 | 2.06 | 30,429 | |
01/29/2025 | 2.07 | 2.27 | 2.01 | 2.11 | 45,683 | |
01/28/2025 | 2.11 | 2.26 | 2.07 | 2.10 | 59,287 | |
01/27/2025 | 2.35 | 2.48 | 2.04 | 2.04 | 92,275 | |
01/24/2025 | 2.28 | 2.43 | 2.26 | 2.42 | 30,230 | |
01/23/2025 | 2.44 | 2.44 | 2.26 | 2.38 | 22,787 | |
01/22/2025 | 2.34 | 2.43 | 2.20 | 2.37 | 29,596 | |
01/21/2025 | 2.38 | 2.44 | 2.30 | 2.31 | 25,599 | |
01/17/2025 | 2.51 | 2.51 | 2.32 | 2.39 | 72,519 | |
01/16/2025 | 2.38 | 2.50 | 2.32 | 2.33 | 87,082 | |
01/15/2025 | 2.46 | 2.63 | 2.35 | 2.35 | 94,912 | |
01/14/2025 | 2.24 | 2.62 | 2.24 | 2.52 | 114,906 | |
01/13/2025 | 2.20 | 2.58 | 1.99 | 2.39 | 3,876,205 | |
01/10/2025 | 2.55 | 2.66 | 2.51 | 2.65 | 35,420 | |
01/08/2025 | 2.75 | 2.75 | 2.55 | 2.55 | 25,154 | |
01/07/2025 | 3.05 | 3.05 | 2.84 | 2.87 | 102,333 | |
01/06/2025 | 3.08 | 3.10 | 2.95 | 2.99 | 86,415 | |
01/03/2025 | 2.99 | 3.10 | 2.92 | 3.00 | 28,308 | |
01/02/2025 | 2.99 | 3.05 | 2.80 | 2.94 | 26,998 | |
12/31/2024 | 3.16 | 3.16 | 3.05 | 3.05 | 51,423 | |
12/30/2024 | 2.93 | 3.20 | 2.61 | 3.05 | 77,930 | |
12/27/2024 | 3.04 | 3.14 | 2.80 | 3.02 | 90,889 | |
12/26/2024 | 2.86 | 3.20 | 2.82 | 3.09 | 291,756 | |
12/24/2024 | 3.03 | 3.39 | 2.72 | 3.20 | 651,001 | |
12/23/2024 | 3.24 | 4.10 | 2.42 | 2.81 | 20,856,580 | |
12/20/2024 | 1.96 | 2.09 | 1.72 | 1.75 | 86,834 | |
12/19/2024 | 2.19 | 2.19 | 1.86 | 1.92 | 32,615 | |
12/18/2024 | 2.50 | 2.55 | 2.05 | 2.05 | 82,296 | |
12/17/2024 | 2.51 | 2.71 | 2.47 | 2.49 | 29,187 | |
12/16/2024 | 2.93 | 2.94 | 2.50 | 2.51 | 18,973 |
About GT Biopharma Stock history
GT Biopharma investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for GTBP is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in GT Biopharma will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing GT Biopharma stock prices may prove useful in developing a viable investing in GT Biopharma
Last Reported | Projected for Next Year | ||
Common Stock Shares Outstanding | 1.9 M | 1.5 M | |
Net Loss | -52.2 M | -54.8 M |
GT Biopharma Stock Technical Analysis
GT Biopharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Did you try this?
Run Performance Analysis Now
Performance AnalysisCheck effects of mean-variance optimization against your current asset allocation |
All Next | Launch Module |
GT Biopharma Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for GT Biopharma's price direction in advance. Along with the technical and fundamental analysis of GTBP Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of GTBP to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
Risk Adjusted Performance | 0.0436 | |||
Jensen Alpha | 0.5325 | |||
Total Risk Alpha | 1.6 | |||
Sortino Ratio | 0.0755 | |||
Treynor Ratio | 0.2621 |
Cycle Indicators | ||
Math Operators | ||
Math Transform | ||
Momentum Indicators | ||
Overlap Studies | ||
Pattern Recognition | ||
Price Transform | ||
Statistic Functions | ||
Volatility Indicators | ||
Volume Indicators |
Additional Tools for GTBP Stock Analysis
When running GT Biopharma's price analysis, check to measure GT Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GT Biopharma is operating at the current time. Most of GT Biopharma's value examination focuses on studying past and present price action to predict the probability of GT Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GT Biopharma's price. Additionally, you may evaluate how the addition of GT Biopharma to your portfolios can decrease your overall portfolio volatility.